Last checked at 27 Jul 2015 07:00
27 July 2015
Allergy Therapeutics plc
Director Share Dealings
On 24 July 2015, the Board of Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") was informed that on 24 July 2015, Manuel Llobet, Chief Executive Officer, purchased 50,000 ordinary shares of 0.10p ("Ordinary Shares") at a price of 24.45p per share. Mr Llobet's beneficial holding now stands at 3,175,000 Ordinary Shares, which represents 0.58% of the issued share capital of the Company to which voting rights are attached.
- Ends -
For further information:
Allergy Therapeutics | +44 (0) 1903 845 820 |
Ian Postlethwaite, Finance Director | |
Panmure Gordon | +44 (0) 20 7886 2500 |
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance | |
Tom Salvesen, Corporate Broking | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Victoria Foster Mitchell |
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.